<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01205464</url>
  </required_header>
  <id_info>
    <org_study_id>151:2004/25331</org_study_id>
    <nct_id>NCT01205464</nct_id>
  </id_info>
  <brief_title>Effects of Doxycycline on Persistent Symptoms Post-neuroborreliosis</brief_title>
  <official_title>Immunomodulatory and Clinical Effects of Doxycycline on Persistent Symptoms After Treatment of Neuroborreliosis: A Double-blind, Randomised, Crossover Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Linkoeping University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Linkoeping University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this randomised, double-blind crossover study was to determine whether Doxycycline&#xD;
      has an impact on the persistent symptoms post-neuroborreliosis, through alterations in the&#xD;
      immune response and whether such an effect could influence the clinical outcome.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Persistent symptoms after treatment of neuroborreliosis (NB) are not uncommon. There is&#xD;
      currently no evidence for improvement of symptoms after repeated or prolonged antibiotic&#xD;
      treatment. However, clinical observations have indicated that some patients improve during&#xD;
      treatment with doxycycline (DOX), but regain the symptoms some time after completed&#xD;
      treatment. This may be due to an immunomodulatory effect of the drug. The aim of this&#xD;
      randomised, double-blind crossover study was to determine whether DOX has an impact on the&#xD;
      persistent symptoms through alterations in the immune response and whether such an effect can&#xD;
      influence the clinical outcome.&#xD;
&#xD;
      A total of 15 patients from South-East Sweden with previously adequately diagnosed NB with&#xD;
      diverse persistent symptoms ≥6months after antibiotic treatment were randomised in a&#xD;
      double-blind, crossover fashion to receive either DOX 200 mg or placebo (PBO) once daily for&#xD;
      three weeks, followed by a wash-out period of six weeks and a further three-weeks treatment&#xD;
      with either DOX 200 mg or PBO once daily for three weeks. The primary outcome measures were&#xD;
      improvement of the persistent symptoms and physical and mental health, evaluated using the&#xD;
      visual analogue scale (VAS), the 36-item Short-Form General Health Survey (SF-36) and through&#xD;
      physical examination with special emphasis on neurologic status at the follow-up visits.&#xD;
      Secondary outcome measures were changes in drug-induced antigen-stimulated and unstimulated&#xD;
      cytokine responses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2005</start_date>
  <completion_date type="Actual">February 2008</completion_date>
  <primary_completion_date type="Actual">February 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement in persistent symptoms</measure>
    <time_frame>12 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in cytokine levels in plasma/serum in patients during treatment with DOX/PBO</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Fatigue</condition>
  <condition>Radicular Pain</condition>
  <condition>Cognitive Dysfunction</condition>
  <condition>Paresthesia</condition>
  <condition>Paresis</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with Capsule Doxycycline 200 mg, once daily, for 21 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Capsule Placebo, 200 mg, once daily, for 21 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.</description>
    <arm_group_label>Doxycycline</arm_group_label>
    <other_name>Doxyferm</other_name>
    <other_name>Vibramycin</other_name>
    <other_name>Tetracycline</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  a history of adequately diagnosed and treated neuroborreliosis (presence of&#xD;
             intrathecal borrelia-antibody production)&#xD;
&#xD;
          -  persistence of symptoms (with debut in conjunction with neuroborreliosis) of typical&#xD;
             character, such as headache, radiculitis, cognitive dysfunction, fatigue, mood&#xD;
             disorders, paresthesia or paresis &gt; 6 months post-treatment of neuroborreliosis&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  systemic immunosuppression (treatment with corticosteroids, cytostatics etc)&#xD;
&#xD;
          -  ongoing infection at inclusion&#xD;
&#xD;
          -  allergy against doxycycline&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breast feeding&#xD;
&#xD;
          -  psychiatric disease&#xD;
&#xD;
          -  multiple sclerosis&#xD;
&#xD;
          -  rheumatoid arthritis&#xD;
&#xD;
          -  diabetes mellitus type 1 or II&#xD;
&#xD;
          -  inflammatory systemic diseases&#xD;
&#xD;
          -  liver ohc kidney dysfunction&#xD;
&#xD;
          -  treatment with didanosine, quinapril, antacids&#xD;
&#xD;
          -  malignancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pia Forsberg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Infectious Diseases, Faculty of Health Sciences, Linköping university, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic for Infectious Diseases, University Hospital</name>
      <address>
        <city>Linköping</city>
        <state>Östergötland</state>
        <zip>58185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>February 2005</verification_date>
  <study_first_submitted>September 17, 2010</study_first_submitted>
  <study_first_submitted_qc>September 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 20, 2010</study_first_posted>
  <last_update_submitted>September 17, 2010</last_update_submitted>
  <last_update_submitted_qc>September 17, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>Pia Forsberg</name_title>
    <organization>Dep. of Infectious Diseases, Faculty of Health Scienses, Linköping University, Sweden</organization>
  </responsible_party>
  <keyword>Persistent symptoms</keyword>
  <keyword>Doxycycline</keyword>
  <keyword>Placebo</keyword>
  <keyword>Neuroborreliosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paresis</mesh_term>
    <mesh_term>Paresthesia</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

